(EN) The disclosure concerns A3AR ligand for reducing ectopic fat accumulation, particularly in fatty liver. Also provided by the disclosure is the use of A3AR ligand for the preparation of a pharmaceutical composition for reducing such fat accumulation, a method of treating a condition associates with fat accumulation making use of the ligand and kits comprising pharmaceutical compositions comprisingthe ligand, and instructions for use of same, for treating a condition associated with ectopic fat accumulation. In one embodiment, the disclosure provides the use of an A3AR agonist, such as 2-Chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (C1-IB-MECA, CF102) for treating fatty liver, specifically, non-alcoholic fatty liver disease (NAFLD).
(ZH) 本公开内容涉及用于减少异位脂肪堆积、特别是脂肪肝中的异位脂肪堆积的A3AR配体。本公开内容还提供了A3AR配体用于制备用于减少这样的脂肪堆积的药物组合物的用途、利用该配体治疗与脂肪堆积相关的状况的方法、以及试剂盒，试剂盒包括含有该配体的药物组合物和使用药物组合物来治疗与异位脂肪堆积相关的状况的使用说明。在一个实施方案中，本公开内容提供A3AR激动剂例如2‑氯‑N6‑(3‑碘苄基)‑腺苷‑5'‑N‑甲基脲酰胺(Cl‑IB‑MECA，CF102)用于治疗脂肪肝、尤其是非酒精性脂肪肝病(NAFLD)的用途。
